In a significant move likely to reshape the competitive landscape, the FDA has granted approval for Novartis’ Kisqali, when paired with an aromatase inhibitor, for the adjuvant treatment of HR-positive, HER2-negative stage 2 and 3 breast cancer at high risk of recurrence post-surgery. This approval
The world of cancer treatment is ever-evolving, and recent developments have brought a glimmer of hope for those battling non-small cell lung cancer (NSCLC). iTeos Therapeutics has unveiled promising results from a mid-stage clinical trial examining the efficacy of combining their drug,
Recent advancements in cancer treatments have provided new hope for patients, with significant progress showcased in the biopharmaceutical industry. The interim results of ArriVent BioPharma, Inc.'s Phase 1b FURTHER trial for their drug firmonertinib have been particularly promising. This trial
In a significant advancement for non-small cell lung cancer (NSCLC) treatment, Akeso and Summit Therapeutics have revealed astounding results from their phase 3 HARMONi-2 trial. Ivonescimab, a PD-1/VEGF bispecific antibody, has demonstrated remarkable efficacy against Merck’s Keytruda, positioning
In the evolving landscape of cancer treatment, the advent of immunotherapies Keytruda and Opdivo has marked a groundbreaking shift. Over the last decade, these drugs, known as PD1 inhibitors, have revolutionized oncology, offering new hope and significantly altering patient outcomes. Their story is
The landscape of biopharmaceutical research and development (R&D) has seen a remarkable evolution, particularly in the realm of oncology. In recent years, a significant portion of R&D investments has been channeled into cancer research, paving the way for groundbreaking treatments and therapies.
